Evidence map›Paper›PMID 20932301›Full record

ArticleRespiratory research2010

Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients.

Deanna M Green, Kathryn E McDougal, Scott M Blackman, Patrick R Sosnay, Lindsay B Henderson, Kathleen M Naughton, J Michael Collaco, Garry R Cutting

Open access · goldAbstract readComparative StudyTwin Study
In one paragraph

Article in Respiratory research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2012
    Trial
  4. Longitudinal changes in the cystic fibrosis airway microbiota with time and treatment.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Club cell secretory protein and lung function in children with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022
    Article
  9. Pseudomonas aeruginosa in the Cystic Fibrosis Lung.Advances in experimental medicine and biology · 2022
    Article
  10. CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling.American journal of physiology. Lung cellular and molecular physiology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019
    Article
  17. Article
  18. Article
  19. Early severe anemia as the first sign of cystic fibrosis.European journal of pediatrics · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Deanna M GreenMcKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kathryn E McDougal
Scott M Blackman
Patrick R Sosnay
Lindsay B Henderson
Kathleen M Naughton
J Michael Collaco
Garry R Cutting
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Genetic Modifiers of Cystic Fibrosis: Sibling StudyR01HL068927 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CUTTING, GARRY R · 2001 to 2011
$8.9M
Multidisciplinary Training Program in Pediatric PulmonaryT32HL072748 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Joseph Michael Collaco · 2003 to 2026
$6.1M
Modifier genes in CF-related diabetes and meconium ileusF32DK076446 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI BLACKMAN, SCOTT M · 2006 to 2007
$117k
NHLBI NIH HHS HL068927NHLBI NIH HHS R01 HL068927NHLBI NIH HHS T32 HL072748NIDDK NIH HHS DK076446NIDDK NIH HHS DK99003
6 · The paper itself

Abstract

backgroundLung infection by various organisms is a characteristic feature of cystic fibrosis (CF). CFTR genotype effects acquisition of Pseudomonas aeruginosa (Pa), however the effect on acquisition of other infectious organisms that frequently precede Pa is relatively unknown. Understanding the role of CFTR in the acquisition of organisms first detected in patients may help guide symptomatic and molecular-based treatment for CF.

methodsLung infection, defined as a single positive respiratory tract culture, was assessed for 13 organisms in 1,381 individuals with CF. Subjects were divided by predicted CFTR function: 'Residual': carrying at least one partial function CFTR mutation (class IV or V) and 'Minimal' those who do not carry a partial function mutation. Kaplan-Meier estimates were created to assess CFTR effect on age of acquisition for each organism. Cox proportional hazard models were performed to control for possible cofactors. A separate Cox regression was used to determine whether defining infection with Pa, mucoid Pa or Aspergillus (Asp) using alternative criteria affected the results. The influence of severity of lung disease at the time of acquisition was evaluated using stratified Cox regression methods by lung disease categories.

resultsSubjects with 'Minimal' CFTR function had a higher hazard than patients with 'Residual' function for acquisition of 9 of 13 organisms studied (HR ranging from 1.7 to 3.78 based on the organism studied). Subjects with minimal CFTR function acquired infection at a younger age than those with residual function for 12 of 13 organisms (p-values ranging: < 0.001 to 0.017). Minimal CFTR function also associated with younger age of infection when 3 alternative definitions of infection with Pa, mucoid Pa or Asp were employed. Risk of infection is correlated with CFTR function for 8 of 9 organisms in patients with good lung function (>90%ile) but only 1 of 9 organisms in those with poorer lung function (<50%ile).

conclusionsResidual CFTR function correlates with later onset of respiratory tract infection by a wide spectrum of organisms frequently cultured from CF patients. The protective effect conferred by residual CFTR function is diminished in CF patients with more advanced lung disease.

Indexed as

AdolescentAdultChildChild, PreschoolCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorFemaleFollow-Up StudiesHumansInfantMaleMiddle AgedMutationRespiratory Tract InfectionsYoung AdultCFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID20932301
PMCPMC2964615
OpenAlexW2002473330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.